Lexaria Bioscience Corp. (LEXX) — SEC Form D Filing
Lexaria Bioscience Corp. (LEXX) filed an SEC Form D on September 21, 2026, reporting $113K raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- September 21, 2026
- Amount reported
- $113K
- Round stage
- Growth stage, as indicated by the company's established revenue of over five million dollars and a small, opportunistic capital raise of one hundred thirteen thousand dollars.
- Industry
- Biotechnology
- Website
- https://www.lexariabioscience.com
What the company does
Revenue: $5,000,001 - $25,000,000. Exemption: Rule 506(b). Incorporated: NEVADA
Problem
Poor bioavailability and slow absorption of lipophilic active pharmaceutical ingredients limit the clinical efficacy and consumer appeal of oral medications and supplements.
Solution
Lexaria Bioscience Corp. (LEXX) develops and licenses its patented DehydraTECH drug delivery technology to improve the speed of onset, bioavailability, and brain penetration of active molecules.
Why now
The surging demand for alternative, non-invasive delivery methods for GLP-1 agonists and cannabinoids requires immediate innovation in oral bioavailability.
Source: SEC EDGAR Form D filing